© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Differential cyclin E expression in human in-stent stenosis smooth muscle cells identifies targets for selective anti-restenosis therapy
aDivision of Cardiovascular Medicine, Cambridge University, Box 110, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK
bCardiac Unit, Papworth Hospital, Cambridge, UK
cDepartment of Neurosurgery, Addenbrooke's Hospital, UK
*Corresponding author. Tel.: +44-1223-331504; fax: +44-1223-331505. Email address: mrb{at}mole.bio.cam.ac.uk
Objective: Cell cycle inhibitors are promising agents to prevent or treat human coronary in-stent stenosis (ISS). However, their lack of specificity for ISS vascular smooth muscle cells (VSMCs) may inhibit medial VSMC proliferation and suppress vessel healing. Methods: To identify inhibitor targets that differentially regulate proliferation of ISS vs. medial VSMCs, we examined cell cycle regulation in human VSMCs derived from (A) normal media, (B) ISS sites and (C) primary atherosclerotic plaques (P-VSMCs) using time-lapse videomicroscopy, flow cytometry, immunoblotting and immunohistochemistry. Results: ISS-VSMC proliferation was intermediate between P-VSMCs and medial VSMCs. Compared with medial cells, P-VSMCs expressed increased p16 and p21, reduced p27, reduced cyclins D1 and E, and reduced pRb phosphorylation. In contrast, ISS-VSMCs expressed high levels of cyclins E and A with pRb hyperphosphorylation, both in vitro and in vivo, associated with increased and chronic cell proliferation in vivo. Roscovitine, a selective CDK2 inhibitor, inhibited VSMC proliferation by both pRb-dependent and independent pathways and more potently in ISS-VSMCs than medial VSMCs. Conclusions: Human ISS-VSMCs have marked differences in the stable expression of multiple cell cycle regulators, suggesting that ISS-VSMCs derive from P-VSMCs driven to proliferate through cyclin E overexpression. The critical role for cyclin E–CDK2 enables the identification of the first agent that selectively inhibits ISS-VSMC proliferation.
KEYWORDS Restenosis; Smooth muscle; Atherosclerosis
time for primary review 21 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. A. Calvert and M. R. Bennett Restenosis Revisited Circ. Res., April 10, 2009; 104(7): 823 - 825. [Full Text] [PDF]
|
|
|
|
 |
|
 M. R Bennett Vascular pathology as a result of drug-eluting stents Heart, August 1, 2007; 93(8): 895 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gorenne, M. Kavurma, S. Scott, and M. Bennett Vascular smooth muscle cell senescence in atherosclerosis Cardiovasc Res, October 1, 2006; 72(1): 9 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Matthews, I. Gorenne, S. Scott, N. Figg, P. Kirkpatrick, A. Ritchie, M. Goddard, and M. Bennett Vascular Smooth Muscle Cells Undergo Telomere-Based Senescence in Human Atherosclerosis: Effects of Telomerase and Oxidative Stress Circ. Res., July 21, 2006; 99(2): 156 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.W. Fischer Dexamethasone: Effects on neointimal hyperplasia and vessel integrity Cardiovasc Res, December 1, 2005; 68(3): 350 - 352. [Full Text] [PDF]
|
|
|
|
|
|
D. Rosner, N. McCarthy, and M. Bennett Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53 Cardiovasc Res, June 1, 2005; 66(3): 601 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Andres Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential Cardiovasc Res, July 1, 2004; 63(1): 11 - 21. [Abstract] [Full Text] [PDF]
|
|